TNGX Live signaler | Maksimer profitt med Getagraph.com

SELG 117052 min ago

@ $11.71

Utstedt: 13 feb 2024 @ 21:42

Avkastning: -35.01%

Forrige signal: feb 13 - 15:30

Forrige signal: Kjøp

Avkastning: -1.76 %

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):

Stats
Dagens volum	330 699
Gjennomsnittsvolum	613 856
Markedsverdi	812.25M
EPS	$0 ( 2024-03-25 )
Neste inntjeningsdato	( $-0.310 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-7.05
ATR14	$0.00800 (0.11%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-01	Mva Investors, Llc	Sell	75 000	Common Stock
2024-05-02	Mva Investors, Llc	Sell	75 000	Common Stock
2024-05-03	Mva Investors, Llc	Sell	60 000	Common Stock
2024-02-20	Third Rock Ventures Iv, L.p.	Sell	162 500	Common Stock
2024-02-06	Weber Barbara	Sell	4 681	Common Stock

INSIDER POWER
87.11
Last 93 transactions
Buy: 16 052 308 \| Sell: 875 313

Volum Korrelasjon

Lang: -0.01 (neutral)

Kort: -0.73 (moderate negative)

Signal:(58.905) Neutral

Tango Therapeutics, Inc. Korrelasjon

10 Mest positive korrelasjoner
GSMG	0.949
CMLS	0.947
AADI	0.942
AKTX	0.938
DSWL	0.934
TTCF	0.93
DRUG	0.929
INTA	0.928
ACRX	0.928
AROW	0.927

10 Mest negative korrelasjoner
MORF	-0.946
CNCE	-0.937
TYHT	-0.934
INOD	-0.93
PLYA	-0.923
EPZM	-0.923
BZ	-0.921
LFMD	-0.918
MOTNU	-0.917
ITI	-0.914

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Tango Therapeutics, Inc. Korrelasjon - Valuta/Råvare

-0.14
( neutral )

-0.22
( neutral )

0.00
( neutral )

0.14
( neutral )

-0.31
( neutral )

-0.26
( neutral )

Tango Therapeutics, Inc. Økonomi

Annual	2023
Omsetning:	$36.53M
Bruttogevinst:	$34.11M (93.39 %)
EPS:	$-1.080

FY	2023
Omsetning:	$36.53M
Bruttogevinst:	$34.11M (93.39 %)
EPS:	$-1.080

FY	2022
Omsetning:	$24.86M
Bruttogevinst:	$20.83M (83.80 %)
EPS:	$-1.230

FY	2021
Omsetning:	$37.04M
Bruttogevinst:	$37.04M (100.00 %)
EPS:	$-3.49

Financial Reports:

No articles found.

Tango Therapeutics, Inc.

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.